Herceptin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerOvarian CancerGastric CancerAcute Lymphoblastic LeukemiaGrowth

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Herceptin

Roche

Approved

512

Adriamycin

GGynecologic Oncology Group

Preclinical

873

Gemzar

GGynecologic Oncology Group

Preclinical

224

Chirocaine

PPurdue Pharma LP

Preclinical

15

Chantix

PPrism Pharmaceuticals

Preclinical

16

Feraheme

AAzurity Pharmaceuticals

Preclinical

17

Vfend

PPrism Pharmaceuticals

Preclinical

—8

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

19

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

110

Lipegfilgrastim

Merck & Co.

Preclinical

1Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer51 trials

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 1/2·NCT00129896·73 enrolled

Herceptin and GM-CSF for Metastatic Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00429104·18 enrolled

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Terminated·HHellenic Oncology Research Group·Phase 3·NCT00440622·90 enrolled

Show 48 more trials

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Completed·NNSABP Foundation Inc·Phase 3·NCT00004067·2,130 enrolled

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Completed·Pfizer·Phase 1/2·NCT00031278·12 enrolled

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

Completed·EEric Winer, MD·Phase 2·NCT00148668·81 enrolled

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Active, not recruiting·MMedSIR·Phase 2·NCT03161353·377 enrolled

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Completed·—·Phase 2·NCT00136539·41 enrolled

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Completed·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05629949·474 enrolled

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Terminated·UUniversity of Washington·Phase 1/2·NCT00041470·38 enrolled

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Completed·Pfizer·Phase 3·NCT01989676·707 enrolled

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Completed·NNanogen Pharmaceutical Biotechnology Joint Stock Company·Phase 3·NCT05301010·128 enrolled

Neoadjuvant Herceptin in Patients With Breast Cancer

Terminated·MMothaffar Rimawi·Phase 2·NCT00133796·40 enrolled

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed·PPalleos Healthcare GmbH·Phase 2·NCT03272477·257 enrolled

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Completed·Sanofi·Phase 3·NCT00021255·3,222 enrolled

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038402·74 enrolled

Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00943410·19 enrolled

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer

Unknown status·RRuijin Hospital·Phase 2·NCT03907800·100 enrolled

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT03879577·53 enrolled

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Completed·Pfizer·Phase 1·NCT00372424·26 enrolled

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Completed·Roche·Phase 2·NCT00545688·417 enrolled

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Completed·Pfizer·Phase 2·NCT00043394·16 enrolled

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

Completed·SShanghai Institute Of Biological Products·Phase 3·NCT03989037·580 enrolled

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Completed·Bristol-Myers Squibb·Phase 2·NCT00093145·32 enrolled

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Terminated·SSamsung Bioepis Co., Ltd.··NCT02771795·538 enrolled

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

Completed·Roche·Phase 4·NCT00127933·157 enrolled

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

Completed·SSamsung Bioepis Co., Ltd.·Phase 3·NCT02149524·875 enrolled

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Terminated·SSwiss Cancer Institute·Phase 3·NCT00004935·175 enrolled

A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients

Completed·PPrestige Biopharma Limited·Phase 3·NCT03013504·503 enrolled

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Completed·Roche·Phase 3·NCT01566721·2,577 enrolled

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Completed·NNanogen Pharmaceutical Biotechnology Joint Stock Company·Phase 1·NCT05301530·50 enrolled

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

Completed·Shanghai Henlius Biotech·Phase 3·NCT03084237·652 enrolled

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

Completed·Roche·Phase 3·NCT00045032·5,099 enrolled

Preoperative Herceptin and Navelbine for Breast Cancer

Completed·—·Phase 2·NCT00148681·49 enrolled

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

Completed·EEirGenix, Inc.·Phase 3·NCT03433313·807 enrolled

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Completed·—·Phase 2·NCT01004172·38 enrolled

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Terminated·TTranslational Oncology Research International·Phase 2·NCT00138125·2 enrolled

A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Completed·Roche·Phase 1/2·NCT00337649·27 enrolled

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Completed·TTanvex BioPharma USA, Inc.·Phase 3·NCT03556358·809 enrolled

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00118053·5 enrolled

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00433095

Adj TC + Herceptin Early Stage Breast Cancer

Completed·UUS Oncology Research·Phase 2·NCT00493649·493 enrolled

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

Completed·NNancy Lin, MD·Phase 1·NCT00470847·35 enrolled

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Completed·Roche·Phase 3·NCT00391092·424 enrolled

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

Completed·Roche·Phase 2·NCT02748213·225 enrolled

Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients

Suspended·NNational Guard Health Affairs··NCT02062983·50 enrolled

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Completed·Eli Lilly·Phase 2·NCT00191451·150 enrolled

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Completed·NNancy Lin, MD·Phase 2·NCT00470704·87 enrolled

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00453635·88 enrolled

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Completed·Roche·Phase 2·NCT01401166·488 enrolled

Demonstrate Efficacy and Safety of Metastatic Breast Cancer

Completed·CCelltrion·Phase 3·NCT01084876·475 enrolled

Tics2 trials

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

Completed·UUnited BioPharma·Phase 1·NCT03013881·18 enrolled

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05765357·89 enrolled

Growth2 trials

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Terminated·Roche·Phase 3·NCT01450696·296 enrolled

A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

Completed·Roche·Phase 1·NCT00800436·66 enrolled

Gastric Cancer1 trial

Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis

Unknown status·HHebei Medical University·Phase 4·NCT02380131·60 enrolled

Cancer of the Pancreas1 trial

Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00005926·50 enrolled

13 more indications

Efficacy1 trial

Evaluate Safety, Efficacy and Pharmacokinetics

Completed·CCelltrion·Phase 1/2·NCT01084863·143 enrolled

Ovarian Cancer1 trial

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

Terminated·AARCAGY/ GINECO GROUP·Phase 2·NCT00189579·45 enrolled

MPA1 trial

A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)

Completed·Pfizer·Phase 1·NCT01603264·105 enrolled

Acute Lymphoblastic Leukemia1 trial

Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Terminated·NNantes University Hospital·Phase 2·NCT00724360·15 enrolled

Neoadjuvant Treatment1 trial

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Completed·TTanvex BioPharma USA, Inc.·Phase 3·NCT04109391·338 enrolled

Ductal Carcinoma in Situ1 trial

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

Completed·MM.D. Anderson Cancer Center·N/A·NCT00496808·69 enrolled

Cancer1 trial

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Completed·Boehringer Ingelheim·Phase 1·NCT01649271·13 enrolled

Breast Tumors1 trial

Prognostic and Predictive Factors for Small Breast Tumors

Completed·KKarolinska Institutet··NCT03390608·35,002 enrolled

Single Dose1 trial

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Completed·GGenor Biopharma Co., Ltd.·Phase 1·NCT04905667·87 enrolled

Locally Advanced Cancer1 trial

A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer

Completed·Roche·Phase 3·NCT02721641·69 enrolled

Efficacy and Safety1 trial

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04385563·338 enrolled

Immunotherapy1 trial

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Completed·GGeorge E. Peoples·Phase 2·NCT01570036·275 enrolled

Unspecified2 trials

A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)

Completed·Pfizer·Phase 1·NCT02015156·162 enrolled

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male Subjects

Completed·Shanghai Henlius Biotech·Phase 1·NCT02581748·123 enrolled

Details

Drug Info

Related News